腱滑膜巨细胞瘤（TGCT）是一种罕见的肌肉骨骼系统良性肿瘤。由于高复发率，手术治疗充满挑战。本研究的目的是描述澳大利亚肌肉骨骼肿瘤三级转诊中心的 TGCT 手术治疗和手术结果评估，并确定影响复发率的因素。对由两名骨科肿瘤外科医生进行手术管理的所有 TGCT 患者的前瞻性数据库进行了审查。所有病例，无论之前是否接受过治疗，都被纳入其中，没有随访的患者被排除在外。收集相关肿瘤特征和手术结果进行分析。本研究共纳入111例病例； 71 名 (64%) 为女性，平均年龄为 36 岁 (SD 13.6)，膝关节 (n = 64; 57.7%) 是最常受影响的关节。总共有 60 名患者 (54.1%) 患有弥漫型 (D-TGCT) 疾病，94 名患者 (84.7%) 表现为“原发病例”(PC)，未接受治疗。 TGCT 的总体复发率为 46.8%。 D-TGCT 和局部疾病之间的复发率存在统计学显着差异（75.0% vs 13.7%，相对风险 (RR) 3.40，95% 置信区间 (CI) 2.17 至 5.34；p < 0.001）。与 PC 组相比，被转入“翻修病例”(RC) 组（82.4% vs 48.9%，RR 1.68，95% CI 1.24 至 2.28；p = 0.011）。年龄、性别、肿瘤体积和平均症状持续时间与复发无关（p > 0.05）。即使在三级转诊医院，复发率仍然很高。最高比率出现在 D-TGCT 和“翻修病例”中。由于复发风险、手术复杂性以及辅助治疗的需要，本文进一步支持在三级转诊多学科骨科肿瘤服务中进行 TGCT 管理。© 2023 Kim 等人。

Tenosynovial giant cell tumour (TGCT) is a rare benign tumour of the musculoskeletal system. Surgical management is fraught with challenges due to high recurrence rates. The aim of this study was to describe surgical treatment and evaluate surgical outcomes of TGCT at an Australian tertiary referral centre for musculoskeletal tumours and to identify factors affecting recurrence rates.A prospective database of all patients with TGCT surgically managed by two orthopaedic oncology surgeons was reviewed. All cases irrespective of previous treatment were included and patients without follow-up were excluded. Pertinent tumour characteristics and surgical outcomes were collected for analysis.There were 111 total cases included in the study; 71 (64%) were female, the mean age was 36 years (SD 13.6), and the knee (n = 64; 57.7%) was the most commonly affected joint. In all, 60 patients (54.1%) had diffuse-type (D-TGCT) disease, and 94 patients (84.7%) presented therapy-naïve as "primary cases" (PC). The overall recurrence rate was 46.8% for TGCT. There was a statistically significant difference in recurrence rates between D-TGCT and localized disease (75.0% vs 13.7%, relative risk (RR) 3.40, 95% confidence interval (CI) 2.17 to 5.34; p < 0.001), and for those who were referred in the "revision cases" (RC) group compared to the PC group (82.4% vs 48.9%, RR 1.68, 95% CI 1.24 to 2.28; p = 0.011). Age, sex, tumour volume, and mean duration of symptoms were not associated with recurrence (p > 0.05).Recurrence rates remain high even at a tertiary referral hospital. Highest rates are seen in D-TGCT and "revision cases". Due to the risks of recurrence, the complexity of surgery, and the need for adjuvant therapy, this paper further supports the management of TGCT in a tertiary referral multi-disciplinary orthopaedic oncology service.© 2023 Kim et al.